Literature DB >> 27292107

Augmented Activity of Cyclooxygenase-2 in Tissue and Serum of Patients With Cervical Cancer.

Poonam Jawanjal1, Sudha Salhan2, Indrani Dhawan3, Nirmalendu Das4, Ruby Aggarwal1, Richa Tripathi5, Gayatri Rath6.   

Abstract

BACKGROUND: Cyclooxygenase-2 (Cox-2) is frequently overexpressed in cervical carcinoma, but little is known about its altered serum concentration. Hence, this study evaluates clinical utility of cellular and serum level of Cox-2 enzyme in cervical cancer.
METHODS: The expression of Cox-2 was evaluated in cervical tissues and serum samples collected from normal controls (n = 100; n = 68), cervical intraepithelial neoplasia patients (CIN, n = 67; n = 12), and invasive squamous cell carcinoma patients (SCCs; n = 153; n = 127) by immunohistochemical and enzyme-linked immunosorbent assay (ELISA) analyses.
RESULTS: The significant cytoplasmic overexpression of Cox-2 was noted in 50.7% of CIN and 69.9% of SCCs as compared with normal (P = 0.0001). Serum level of Cox-2 was also found to be elevated both in CIN (median 4.35 ng/ml) and in SCCs (median 19.39 ng/ml) with respect to normal (median 0.44 ng/ml; P = 0.0001), respectively. The ROC analysis revealed the potential of serum Cox-2 over its cellular expression to distinguish CIN and SCCs from normal.
CONCLUSION: Augmented Cox-2 activity is implicated in the pathogenesis of cervical cancer, and its serum level could serve a potential to distinguish this malignancy. Therefore, it is suggested that serum Cox-2 may be useful in monitoring the diagnosis and treatment outcome of patients.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  Cox-2; cervical cancer; cervical intraepithelial neoplasia; invasive squamous cell carcinoma

Mesh:

Substances:

Year:  2016        PMID: 27292107      PMCID: PMC6807097          DOI: 10.1002/jcla.22003

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  39 in total

1.  Re: Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme.

Authors:  O Gallo
Journal:  J Natl Cancer Inst       Date:  2000-02-16       Impact factor: 13.506

2.  Cyclooxygenase-2 is overexpressed in human cervical cancer.

Authors:  S Kulkarni; J S Rader; F Zhang; H Liapis; A T Koki; J L Masferrer; K Subbaramaiah; A J Dannenberg
Journal:  Clin Cancer Res       Date:  2001-02       Impact factor: 12.531

3.  Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients.

Authors:  G Ferrandina; L Lauriola; M G Distefano; G F Zannoni; M Gessi; F Legge; N Maggiano; S Mancuso; A Capelli; G Scambia; F O Ranelletti
Journal:  J Clin Oncol       Date:  2002-02-15       Impact factor: 44.544

4.  Clinical significance of inactivated glycogen synthase kinase 3β in HPV-associated cervical cancer: Relationship with Wnt/β-catenin pathway activation.

Authors:  Gayatri Rath; Poonam Jawanjal; Sudha Salhan; Manoharan Nalliah; Indrani Dhawan
Journal:  Am J Reprod Immunol       Date:  2014-12-23       Impact factor: 3.886

5.  Inverse correlation between serum PGE2 and T classification in head and neck cancer.

Authors:  Markus Hambek; Mehran Baghi; Jens Wagenblast; Johannes Schmitt; Helena Baumann; Rainald Knecht
Journal:  Head Neck       Date:  2007-03       Impact factor: 3.147

6.  Overexpression of cyclooxygenase-2 is associated with a poor prognosis in patients with squamous cell carcinoma of the uterine cervix treated with radiation and concurrent chemotherapy.

Authors:  Yong Bae Kim; Gwi Eon Kim; Nam Hoon Cho; Hong Ryull Pyo; Su Jung Shim; Sei Kyung Chang; Hee Chul Park; Chang Ok Suh; Tchan Kyu Park; Byung Soo Kim
Journal:  Cancer       Date:  2002-08-01       Impact factor: 6.860

7.  Assignment of the human prostaglandin-endoperoxide synthase 2 (PTGS2) gene to 1q25 by fluorescence in situ hybridization.

Authors:  A Tay; J A Squire; H Goldberg; K Skorecki
Journal:  Genomics       Date:  1994-10       Impact factor: 5.736

Review 8.  Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung.

Authors:  R E Harris
Journal:  Inflammopharmacology       Date:  2009-04       Impact factor: 4.473

9.  Expression of cyclooxygenase-1 and -2 associated with expression of VEGF in primary cervical cancer and at metastatic lymph nodes.

Authors:  Moon-Hong Kim; Sang-Soo Seo; Yong-Sang Song; Dae-Hee Kang; In-Ae Park; Soon-Beom Kang; Hyo-Pyo Lee
Journal:  Gynecol Oncol       Date:  2003-07       Impact factor: 5.482

10.  Wnt/β-catenin signaling enhances cyclooxygenase-2 (COX2) transcriptional activity in gastric cancer cells.

Authors:  Felipe Nuñez; Soraya Bravo; Fernando Cruzat; Martín Montecino; Giancarlo V De Ferrari
Journal:  PLoS One       Date:  2011-04-06       Impact factor: 3.240

View more
  3 in total

1.  Effect of photodynamic therapy combined with Celecoxib on expression of cyclooxygenase-2 protein in HeLa cells.

Authors:  Yuanfu Mao; Lishuang Wang; Chen Xu; Shiyu Han
Journal:  Oncol Lett       Date:  2018-03-02       Impact factor: 2.967

2.  The Prostaglandin EP3 Receptor Is an Independent Negative Prognostic Factor for Cervical Cancer Patients.

Authors:  Helene Heidegger; Sebastian Dietlmeier; Yao Ye; Christina Kuhn; Aurelia Vattai; Caroline Aberl; Udo Jeschke; Sven Mahner; Bernd Kost
Journal:  Int J Mol Sci       Date:  2017-07-19       Impact factor: 5.923

3.  Inhibition of Wnt-β-Catenin Signaling by ICRT14 Drug Depends of Post-Transcriptional Regulation by HOTAIR in Human Cervical Cancer HeLa Cells.

Authors:  Samuel Trujano-Camacho; David Cantú-de León; Izamary Delgado-Waldo; Jossimar Coronel-Hernández; Oliver Millan-Catalan; Daniel Hernández-Sotelo; César López-Camarillo; Carlos Pérez-Plasencia; Alma D Campos-Parra
Journal:  Front Oncol       Date:  2021-10-28       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.